Interstitial lung diseases Restrictive lung diseases Lung fibrosis

Creative Commons



"small sized" lungs

Extensive fibrosis with emphysematous changes and great pleural thickening:

> visceral, parietal, and diaphragmatic. Lower lobe predominantly involved

Finn Rasmussen







The principle of lung fibrosis

Important -Restriktive lung function



Also seen without problems in the lung parenkyma

The ribs of large curve; the lungs large and roomy; the liver, stomach and bowels in their normal position; all with abundant room. The ribs bent almost to angles; the lungs contracted; the liver, stomach and intestines forced down into the pelvis, crowding the womb seriously.

Nature Versus Corsets Illustrated.



In principle there is are "acute" restriktive disorders

Pleuraexsudate, pneumonia Atelektasis etc..

However. Normally in lungfibrosis

Disease localized in the paremkyma

What is lost is forever lost

... if treatment is not started in time...

What is ILD or DPLD ?

- Diffuse parenchymal lung diseases, often collectively referred to as the interstitial lung diseases (ILDs), but many names are existing for the same disease leading to a lot of confusion in the area
- The term *interstitial* is misleading since most of these disorders are also associated with extensive alterations of alveolar and airway architecture



Normal lung High power photomicrograph shows alveoli



Nonspecific interstitial pneumonia, cellular pattern The

Symptoms

- Signs ٠
- Slowly progession
 - But attracts is prevalent
- Breathlessness ٠
 - At first at activity
 - Later all the time
- cough ٠
 - Non- productive
- Findings cyanosis ٠
 - Low saturation
- low lung function ٠
 - TLC
 - RV
 - dlco
- Dromstikfingers ۲
- Velcro sound at stethoscopy ۲

As proposed by the project









As specified in the project request.







As installed at the user's site.

What the user wanted.





Findings Lung Function

Spirometry reveals a restrictive pattern.

FVC is reduced, but FEV₁/FVC normal/supernormal.

All lung volumes -TLC, FRC, RV – Are Reduced.



CASE

1975, operatted for retentio testis. 1989, operated inqvinal hernia right side.

47 year old male: The Pt. s symptoms started 7 month ago with dry cough, initially treated by a doctor with Salbuvent mixture, but as no effect. Never smoker.

He then stopped the treatment after 3 days due to heart beat and tremor. Cough is mostly dry but intermittent yellow. Had has som pain in the joints without swelling.

The patient has a complain of increasing dyspnea especially the last month. Whezzing has been observed a few times. Some joint pain especially in both shoulders.

Returns to his doctor after 7 month and the doctor due a X-RAY:





CASE

X-RAY showing bilat. Infiltrats and increased size of lympnodes at hilus.

The doctor says pneumonia and gives Klacid 500mg x2

Do you agree ??

How do we approach this patient ?

- Tentative diagnoses
 - Asthma
 - Infection
 - Diffus parenkymatøs lung disease
 - In particular sarcoidosis
 - Cancer
 - lymphoma
- Tests
 - CT- thorax + upper abdomen
 - Bloodtest
 - Lung function incl reversibility
 - Bronkoskopi









Analysenavn	Resultat	r	С	R	Enhed	Ref.lav	Ref.høj	T	Kode	P
Hæmoglobin;B	9,1				mmol/l	8,0	11,0		HB	6
Erytrocytmorf	~~~~~~~~~~								ERYMRF	6
Leukocytter;B	9,1				10E9/1	3,0	10,0		LKC	6
Leukocyttype									LEUTY	6
Neutrofile	7,83			*	10E9/1	1,50	7,50		NEUTRO	6
Eosinofilocytter	0,18				10E9/1	0,04	0,50		EOSINO	6
Basofilocytter	0,00				10E9/1		0,20		BASO	6
Lymfocytter	0,55			*	10E9/1	1,00	3,50		LYMFO	6
Monocytter	0,55				10E9/1	0,20	0,80		MONO	6
Leukocyttype kom	~~~~~								LCTKOM	6
Kreatinin;P	94				µmol/l	62	134		CREA	6
Calcium-ion;S	1,29				mmol/l	1,19	1,29		CAI	6
LD	168				U/1	105	205		LD	6
ALAT	21				U/l	10	70		ALAT	6
BASP	43				U/1	35	105		BASP	6
CRP	<5				mg/l		10		CRP	6
ACE	!KOMM		С		U/1	30	115		ACE	6

ACE= 94 og ANA,ANCA;Anti-CCP: normal; IgG,IgM,IgA,IgE normal EKG= SINUS RYTME no ischemia

LF is technically ok performed; FEV1 =3,14 (65% of predicted), FVC= 4,51 (73% of predicted) A ratio of 70 ?

Bronkoscopy was done

clinic:

cough Xray; diffus infiltrations, also seen on CT. Bronkoskopi: no tumores, mucosa east to bleed.

A: biopsy (Transbronkial) right upper lope

MAKROSKOPI

A: many light very small we try to make some out of it, one tissue done 1 kps/grh

MIKROSKOPI BESKRIVELSE:

Bronkiebiopsiy, surfase has normal respiratorisk

epitel without atypi. Under the epitel mange epiteloidcel-

Granulomea with giantcells. No amyloid. No nekroting granulomatous inflammation,

Why consider diseases with that area . No sign of malignency.

/dpa

Gunvor Madsen

Culture: D+R normal flora PCR was all negative



TEST: Among the diseases mentioned below where do you see Non-caceating granulomas inflammation ???

- 1. COPD
- 2. Asthma
- 3. Idiopatic lungefibrosis
- 4. Sarcoidose
- 5. Allergic alveolitis
- 6. Lymfoma
- 7. Tuberculose
- 8. Wegeners granulomatosis

Among the diseases mentioned below where do NOT see non-caceating granulomas inflammation ??? (casuistik not included)

- 4, 5, 6 og 8 are the right one
 - 1. COPD
 - 2. Asthma
 - 3. Idiopatic lung fibrosis
 - 4. Sarcoidose
 - 5. Allergic alveolitis
 - 6. Lymfoma
 - 7. Tuberculosis
 - 8. Wegeners granulomatosis

More tests for our patients ?

TLC, RV; DLCO; 6 min walking test

30.04.04 we found: TLC: 87 % of predicted RV: 140 % of predicted Diffusionscapacity is decreased to 63 % of predicted FEV 1: 63 % of predicted. FVC 73 % of predicted. The Pattern is slight obstruktive as FEV1/FVC ratio is 70%.

Pt's 6 min. Walking test shows saturations between 93% - 96% and distance of 470 meters. 1 - 2 on Borgs dyspnea skale before test and 4 – 5 after the 6 min..

Diagnosis ?



Resume: 47yrs male cough, dyspnea, joint pains, XRAY shows promint hili, with increased lymfenodes and infiltrative changes in the parymkyma of the lung primarily in hilus and apicalt, FVC 70% of predicted, Peak flow variability is normal. non-caceating granulomas inflammation

Diagnosis ?

- 1. We need further test as we can not be sure yet
- 2. The Patient has sarcoidose
- 3. The Patient has lymfoma
- 4. The Patient has asthma
- 5. The Patient has histeocytosis X
- 6. The Patients allergic Alveolitis
- 7. Wegeners granulomatose

Resume: ~40-årig mand hoste, dyspnø, ledsmerter med prominerede hili, forstørrede lymfeknuder samt infiltrative forandringer hilært og apicalt i lungeparenkymet, Peakflow variabilitet ~10%;

The patient disease : 2 is right

- 1. We need further test as we can not be sure yet
- 2. The Patient has sarcoidose
- 3. The Patient has lymfoma
- 4. The Patient has asthma
- 5. The Patient has histeocytosis X
- 6. The Patients allergic Alveolitis
- 7. Wegeners granulomatose

Diseases





Figure 15-33. Characteristic sarcoid noncaseating granulomas in lung with many giant cells. (Courtesy of Dr. Ramon Blanco, Dept. of Pathology, Brigham and Women's Hospital, Boston.)







Patologi: Non-caceating granulomas disease

Who gets Sarcoidose??

Most often between 25-40 yrs

More women than men

More negro than white



Is Sarcoidose infectious?

NO !

Familiar cases seen !







Klinik Multiorgan disease



Lung symptoms >90%

Cough Dyspnoe Chest pain









Skin changes: Erytema nodosum

Skin Changes



CNS manifestations



10% a debut of parese Often perifer Fasialis parese


Eye symptoms

Send to eye doctor







Sarcoidose treatment **Steroids** Effect on symptoms Effect on lung function Effect on prognose Steroid

- Systemic steroids
- Lokal lokal steroid dependent on organ

+?

• Hypercalciema

More rare treatments:

Andre Immun modulerende stoffer :anti-malaria midler, Metrotrexat, Azathiprine, Infliximab – TNF α blokker.





- Interstitial lung diseases includes different heterogeous diseases of both known and unknown causes but all with inflammation of the interstitium
- The type of inflammatory respons are different and the degree of progression to interstitial fibrosis



Case

60 yrs old man .The Pt symptoms started for 1,5-2 yrs ago, where he for the first time experienced to get severe dyspnea while running. Dry cough . Still working as leader in and institution for disabled. While work works at least 10 km a day. Ex-smoker, for 20 yrs 20 cigarets a day stopped 15 yrs ago.

Bloodtests showed increased IgG, marginally increased ALT, normal IgM reumafaktor. Normal ACE, anti-CCP, ANCA, but weakly positive ANA.

Figur 1. Udpræget clubbing med urglasnegle og hyperæmiske randzoner på højre hånd.

Obj: clubbing,, vencro sound on stetocopy



6 MINUTTERS GANGTEST

• 6760 Ribe

	Dato 7/12-07	Henvisende læge #DM	
	Ilttilskud	Ganghjælpemiddel 🏸	
	TID	DISTANCE	SATURATION
	0 min.	0 m.	91%.
	0,37	50 m.	87%
	1,14	100 m.	85%
	1,53	150 m.	81 %
	2,30	200 m.	79 %
	3,07	250 m.	79%
	3,44	300 m.	79%
	4,19	350 m.	78%
	+ 4,53	400 m.	79 %.
L	town 5,26	450 m.	78°%.
T	6,00	500 m.	78%
		550 m.	
		600 m.	
		650 m.	
		700 m.	
		750 m.	
		800 m.	

Borgs Dyspnøskala (0-10)

FØR	0
EFTER	5

Mette Aulijae

Gangdistance

L

.

UDVIDET LUNGEFUNKTIONSUNDERSØGELSE

Identification:					
First Name:					
Last Name:					
Height:	174,0 cm				
Rel. Weight:	92 %				
Operator:					
Physician:					
Last Test:	1				

	Pred	Act1	Act2	Act3	(A1/P)	%(Best/Pred)
Date		07-07-	-2006			
ATS-ok		0.00				
FEV 1	3.22	2.08			64.6	
FVC	4.10	2.24			54.8	<i>e</i>
FEV1%F		92.71				
JIV1		1.72				
MIF		0.68				
MEF		0.44				
PIF		2.47				
AIN						
TLC	6.82	3.41			50.0	
RV	2.39	1.09			45.6	
RV%TLC	37.75	31.97			84.7	
Hb		15.40				
TLCOC	9.28	2.97			32.0	
KCOC	1.36	0.98			72.4	





HRCT skan

Kontrast: Gantry: 0° FoV: 371 mm Tid: 750 ms Snit: 2 mm Pos: -640 HFP







Kontrast: Gantry: 0° FoV: 371 mm Tid: 750 ms Snit: 2 mm Pos: -720 HFP

F: B70s 200 mA 140 kV Billednr.: 15 Billede 15 af 16



Bronchial lavage for flow cytometri is done and shows total cellenumber of 26 mio., distribution is 66% makrofags, 2% lymfocyttes, 32% granulocyttes and of those 28% is neutrofile og 4% er eosinofile.

Biospsy is suboptimal material very few parts of interstitielt lung tissue, nor enough to make a diagnosis. But signs of few active cells and some fibrosis.

Resume:61 årig man, subjektive progression over 2 years, clubbing and vencrosound on stetoscopy; ANA positiv, 6 min walk sat. fra 91-78%, TLC 50%, diffusion: 32%; bronko. Shows inflammation with fibrosis og HRCT honny combing, tractions bronkieectasiers primary in the lowest lung part

Diagnosis?

- 1. Patient has restriktive lung disease
- 2. Patient has DPLD but the excact diagnose is uncertain
- 3. Patient has allergic alveolis
- 4. Patient has sarcoidosis
- 5. Patienten has asthma
- 6. Patienten has COPD

- 1. Patient has restriktive lung disease
- 2. Patient has DPLD but the excact diagnose is uncertain
- 3. Patienten has allergic alveolis
- 4. Patient has sarcoidosis
- 5. Patienten has asthma
- 6. Patienten has COPD



 Patienten is offered VATS mhp lung biospy to gain a more specific diagnosis

He refuses initially !!!!

Diffuse Parenchymal Lung Disease (DPLD)

Incidence: 1 in ~ 3500

- pulmonary practice ~ 15% of patients

Usually a subacute or chronic clinical presentation with a slowly progressive course

- Exertional dyspnea
- Nonproductive cough
- Hypoxemia
- Restrictive pulmonary function

Many heterogeneous clinicopathologic entities

- Etiology may be known (1/3) or unknown (2/3)

What do we see ? A-gas

- On exercise PaO₂ decreases dramatically.
- Arterial PaO₂ are reduced, pH normal.
- Physiologic dead space and physiologic shunt and VQ mismatch are increased.
- Diffuse impairment contributes to hypoxemia on exercise.
- There is marked reduction in diffusing capacity due to thickening of blood gas barrier and VQ mismatch.

Clinical presentation

Subacute or chronic onset, Exertional dyspnea, nonproductive cough, **Constitutional Symptoms** Tachypnea, digital clubb Inspiratory "velcro" crac Hypoxemia, cor pulmonale

Abnormal chest x-ray

- Reticular, reticulo-nodular patterns
- Distribution (bases, periphery)
- Honeycombing
- Ground-glass pattern (HRCT criteria, not on CXR)

Pulmonary symptoms associated with another disease, such as a connective tissue disease

Lung function abnormalities





– Distribution (bases, periphery)

Setter CIBA Extensive fibrosis with emphysematous changes and great pleural thickening: visceral, parietal, and diaphragmatic. Lower lobe predominantly involved

sbestosis

• One to see !























- 03.04.08
- HRCT shows bronkieektasies in both sides from apex to basis. Lower subpleurale cysts are seen and clasic honney combing seen in idiopatisk lung fibrosis. Apikalt findes øget interstitiel tegning.
- RD: Lung fibrosis with bronkieektasies

- biopsi was done : B: firekantet perfusionsfikseret lungeresektat med stapler på
- to kanten. Resektatet måler 48 x 33 x 8 mm. Vævet fremtræder
- lidt uregelmæssigt med diskrete fibrotiske områder.
- Alt med i 6 kaps. undtagen den staplede kant./jyc
- Undersøger: KEO/pke
- MIKROSKOPI BESKRIVELSE:
- A-B: Alt materialet er indstøbt og undersøgt i histologiske
- snit, hvor der ses heterogent lungevæv. I samme synsfelt
- forekommer normalt lungevæv, fibrose med cystedannelser
- samt område med kronisk inflammation. Der er desuden en
- del sekretstagnation til dilaterede luftveje.
- De inflammatoriske områder viser beskeden inflammatorisk
- aktivitet, overvejende med lymfocytter, men også spredt
- forekomst af eosinofile granulocytter. Der er regeneration
- •

•

- PATIENT: 280639-0359
- med fibroblastiske foci. I perifere luftveje ses bronkial
- metaplasi. I områder med forandringer af mere kronisk
- karakter ses bindevæv samt glat muskelcellehyperplasi.
- Der er ikke granulomer, amyloid eller malignitet.
- Der er en del tykvæggede kar, hvilket opfattes som sekundært
 til lungeforandringerne.
- •
- conclusion :
- good material shows fibroserende alveolitis (UIP). /dpa

Important

The process of achieving a diagnosis in a patient with interstitial lung diseases is dynamic, requiring close communication between clinician, radiologist, and pathologist.

2002 Jan 15;165(2):277-304
Diffuse Parenchymal Lung Disease

There is a single fundamental question which will determine management and prognosis:

Does this patient have idiopathic pulmonary fibrosis?

IPF is the clinical/radiologic equivalent of Usual Interstitial Pneumonia (UIP)

 Empiric treatment is discouraged until a firm diagnosis is established



usual interstitial pneumonia (UIP), fibrotic nonspecific interstitial pneumonia (NSIP), and desquamative interstitial pneumonia (DIP)/respiratory bronchiolitis-associated interstitial lung disease (RBILD)/cellular NSIP

Am. J. Respir. Crit. Care Med., Volume 162, Number 6, Dec. 2000, 2213-2217

Prevalence of subgroup of interstitial pneumonia i 4 studies



Remember !



Restrictive lung diseases are defined by reduced total lung capacity, vital capacity and functional residual capacity, but with preserved air flow

Alteration in lung parenchyma, diseases of the pleura, chest wall or neuromuscular

Lung parenchyma:

Exertional dyspnea, nonproductive cough, Tachypnea, digital clubbing, Inspiratory "velcro" crackles, Hypoxemia, cor pulmonale

Does the patient have UIP ? - important due to treatment and prognosis.

Myths !

 Smoking does NOT normally cause lung fibrosis

- However nothing without exceptions
 Very rare lung diseases
- Smoking gives lungfibrosis....???!!!

The More I Think The More Confused I Get

Smoking-Related Interstitial Lung Disease

Respiratory bronchiolitis
 ILD (RBILD)

Desquamative interstitial
 pneumonia (DIP)

 Pulmonary Langerhans' cell histiocytosis



terminal and respiratory bronchioles









Langerhan cell histiocytosis. This 50-year-old man had a 30 pack-year history of cigarette smoking. A: PA chest radiograph shows hyperinflation of the lungs and fine bilateral reticular ILD.

B: CT scan shows multiple cysts (solid arrow) and nodules (dashed arrow).

>> back | track

Back on Track

FØLG DIN ORDR

...Interesting

TRACK & TRACE

Causes: Restictive lung diseases

- 1. Changes in the lung parenkyma
- 2. Diseases in the pleura, chest wall, muscles and nerves





What happens in lung fibrosis ??











This 50-year-old man presented with end-stage lung fibrosis PA chest radiograph shows medium to coarse reticular B: CT scan shows multiple small cysts (honeycombing) involving predominantly the subpleural peripheral regions of lung. Traction bronchiectasis, another sign of end-stage lung fibrosis.

NORMAL LUNG









Findings

Decrease in saturation under activity
 – Later also at rest

• A-gas shows hypoxia not hypercapnia

– Only in the Terminal fase is hypercapnia seen.

So no problem giving oxygen (in contrast to COPD)

- No tendency to develop hypercapnia

What do we have to measure in patients with lung fibosis??



Fitted to a patient's jaws, the "gnathograph" registers the arrangement of teeth and direction of bite

WITH the aid of the "gnathograph," an instrument as mouth-filling as its name, a dentist's patients may now be assured of a perfect fit for artificial teeth. Fitted to the jaws as shown above, the new device registers the arrangement of the teeth and the direction of the "bite," to guide the dentist in straightening teeth or fitting inlays, crowns, bridges, and plates. Its inventor, Dr. Beverly B. McCollum of Los Angeles, Calif., demonstrates in the picture at the right how the instrument is then mounted for use in tooling a plate to just the right shape to give the most comfortable fit in the mouth. Device Takes Measure of the Teeth



The device then serves as a guide in making plates



There is a slight difference in diagnosing and monitoring the disease

- Lung function
 - Forced volumen
 - TLC, RV and DLCO
- Anatomic changes
 - Bronkoscopy
 - HRCT scan
 - X-RTG Thorax
 - Ekko/hjertekat
 - Lungebiopsy
 - Dexa scanning
- Serological changes
 - Blood tests
- Activity
 - 6 min walking test





Always initially do TLC;RV and DLCO



Odense Universitetshospital * Medicinsk afd. C * Lungemedicinsk/allergologisk sektion

UDVIDET LUNGEFUNKTIONSUNDERSØGELSE



6-min Walking test

- How far?
- Desaturation?
- Symptoms severe ?

6 MINUTTERS GANGTEST

120844-1627 CD L Sørensen,Boris Telling Jasminparken 22 6760 Ribe

Dato 7/12-07	Henvisende læge	HDM
Ilttilskud	Ganghjælpemiddel	ン.

ſ	TID	DISTANCE	SATURATION
	0 min.	0 m.	91%.
	0,37	50 m.	87.9.
	1,14	100 m.	85%
	1,53	150 m.	81 %
	2,30	200 m.	79 %
	3,07	250 m.	79%
	3,44	300 m.	79%
	4,19	350 m.	78%
-	4,53	400 m.	79 %.
Letup	5,26	450 m.	78%
Pt	6,00	500 m.	78%
Γ		550 m.	
aby	voidal ab	11 1+ 10 ^{600 m.}	
JHY	Sical ab	1111 650 m.	
		700 m.	
ſ		750 m.	
ľ		800 m.	

- The test accesses the physical ability?
- Degree of severeness
- Disease development
- Guidance to when transplantation⁽⁰⁻¹⁰⁾ should be considered



HRCT- scan

- Changes
- distribution
- Pattern

Which disease?Who bad?Diffential diagnosis?Further work-up?

- development
 - Effect of treatment
 - Changes in disease



Nielsen,Erik

2705472125

C: 16384.0, B: 16384.0 VE, LIGGE KL. 13.55

21-03-2009, 14:24:57

Odense Universitetshospital F Part @ @ PACS Gateway.... ③ Movell Groupw.... ④ Movell Groupw..... ④ Movell Groupw..... ④ Move

CT versus HRCT

Always HRCT !!!





usual interstitial pneumonia (UIP), fibrotic nonspecific interstitial pneumonia (NSIP), and desquamative interstitial pneumonia (DIP)/respiratory bronchiolitis-associated interstitial lung disease (RBILD)/cellular NSIP

Am. J. Respir. Crit. Care Med., Volume 162, Number 6, Dec. 2000, 2213-2217

Restrictive diseases

Intrinsic lung diseases

- Interstitial lung diseases
 - » Arthritis related (SLE, RA, scleroderma)
 - » "Ideopatic" (ex UIP)
 - "smoke related" (ex Histeocytosis X)
- Asbestosis/silicosis
- Allergic (allergic alveolitis)
- Pleura (debris-exsudat)
- Medicine (nitrofurantoin, amiodarone, bleomycin).
- Pneumonia
- radiation
- Extrinsic diseases (extra-parenchymale diseases)
 - Non-neuromuskular
 - Deformities
 - Heart disease
 - ARDS
 - Neuromuscular
 - Poliomyelitis, Guillain-Barre syndrome, ALS, myasthenia gravis, muscular dystrophies

Inflammation and/or scarring of lung tissue

Fill airspaces exudat/debris (pneumonnitis)

reduced space or muscular power



Treatment

- Immunosupresiva
 - Perferidine
 - Prednisolon
 - One time
 - Continuos
 - Others
 - Azatioprime; metrotrexate, cyclosporine many others
- Anti-inflammatory
 - acetylcysteine
- Removal of cause
 - Allergic alveolitis
 - Langerhans histeocytosis X;REBILD



WINDOW OF OPPORTUNITY

a C.F.'s guide to the transplant experience

 TABLE 1. DISEASE-SPECIFIC GUIDELINES FOR REFERRAL FOR LUNG TRANSPLANTATION.*

Chronic obstructive pulmonary disease

FEV₁ <25 percent of predicted value after bronchodilator therapy Clinically significant hypoxemia, hypercapnia, or pulmonary hypertension; rapid decline in lung function; or frequent severe exacerbations

Idiopathic pulmonary fibrosis

Symptomatic disease unresponsive to medical therapy Vital capacity <60 to 70 percent of predicted value Evidence of resting or exercise-induced hypoxemia

Cystic fibrosis

FEV₁ ≤ 30 percent of predicted value FEV₁ > 30 percent with rapidly declining lung function, frequent severe exacerbations, or progressive weight loss Female sex and age of less than 18 years with FEV₁ > 30 percent[†]

Primary pulmonary hypertension

NYHA functional class III or IV Mean pulmonary-artery pressure >55 mm Hg Mean right atrial pressure >15 mm Hg Cardiac index <2 liters/min/m² Failure of medical therapy, especially intravenous epoprostenol, to improve NYHA functional class or hemodynamic indexes

Eisenmenger's syndrome

NYHA functional class III or IV despite optimal medical management

transplantation is dependent on the disease

CM-104

Worldwide Lung Transplantation Numbers



Source: International Society of Heart and Lung Transplantation (ISHLT); UNOS



Chiron Briefing Document Figure 2.2-1

CM-106

Comparative Transplantation Survival Rates



*Kidney, liver, and heart data extrapolated from OPTN Annual Report, 2003.

Causes of Death Following Lung Transplantation

CM-107



Status for Lung transplantation

- Survivel —50% died after 5 years
- Bronchiolitis obliterans main reason for a bad survivel rate
- Main aim to treat and prevent bronchiolitis obliterans
More time???



